Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

First results of a prospective bendamustine/rituximab trial in patients with MCL

Dr Mathias Rummel - University of Giessen, Giessen, Germany

First results of a prospective bendamustine/rituximab trial in patients with MCL ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Global drug pricing: How cost-effective is bevacizumab?

Dr Daniel Goldstein - Emory University, Atlanta, USA

Global drug pricing: How cost-effective is bevacizumab? ( Dr Daniel Goldstein - Emory University, Atlanta, USA )

Novel antibody helps patients with advanced gastric cancer live longer

Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany

Novel antibody helps patients with advanced gastric cancer live longer ( Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany )

Antibody drug conjugate shows early promise in small cell lung cancer

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Antibody drug conjugate shows early promise in small cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )

Novel antibody helps patients with advanced gastric cancer live longer

Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany

Novel antibody helps patients with advanced gastric cancer live longer ( Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany )

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Novel daratumumab-based regimen slows multiple myeloma progression

Prof Antonio Palumbo - University of Torina, Turin, Italy

Novel daratumumab-based regimen slows multiple myeloma progression ( Prof Antonio Palumbo - University of Torina, Turin, Italy )

Double stem-cell transplant improves outcomes for children with high-risk...

Dr Julie Park - Seattle Children's Hospital, Seattle, USA

Double stem-cell transplant improves outcomes for children with high-risk neuroblastoma ( Dr Julie Park - Seattle Children's Hospital, Seattle, USA )

Advanced hepatocellular carcinoma and personalised therapy

Dr Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA

Advanced hepatocellular carcinoma and personalised therapy ( Dr Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )

Precision medicine selection with MyPathway for solid tumours

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

Precision medicine selection with MyPathway for solid tumours ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin

Dr Hope Rugo - University of California, San Francisco, USA

Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin ( Dr Hope Rugo - University of California, San Francisco, USA )

More from ecancer